ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 128 filers reported holding ATEA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $795,276 | -50.5% | 265,092 | -38.3% | 0.00% | – |
| Q2 2023 | $1,606,314 | +0.5% | 429,496 | -10.0% | 0.00% | – |
| Q1 2023 | $1,598,571 | -24.3% | 477,185 | +8.6% | 0.00% | – |
| Q4 2022 | $2,112,715 | -25.2% | 439,234 | -11.6% | 0.00% | – |
| Q3 2022 | $2,826,000 | +1.4% | 496,980 | +26.6% | 0.00% | – |
| Q2 2022 | $2,787,000 | -10.0% | 392,516 | -8.4% | 0.00% | – |
| Q1 2022 | $3,095,000 | -46.1% | 428,621 | -33.3% | 0.00% | -100.0% |
| Q4 2021 | $5,746,000 | -63.0% | 642,742 | +45.2% | 0.00% | -50.0% |
| Q3 2021 | $15,520,000 | -8.5% | 442,686 | -43.9% | 0.00% | 0.0% |
| Q2 2021 | $16,954,000 | +370.8% | 789,348 | +1253.5% | 0.00% | +100.0% |
| Q1 2021 | $3,601,000 | -19.1% | 58,321 | -45.3% | 0.00% | 0.0% |
| Q4 2020 | $4,453,000 | – | 106,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $17,648,000 | 2.07% |
| EcoR1 Capital, LLC | 6,340,639 | $45,019,000 | 1.55% |
| CM Management, LLC | 200,000 | $1,420,000 | 1.51% |
| K2 PRINCIPAL FUND, L.P. | 1,606,059 | $11,403,000 | 1.26% |
| Cormorant Asset Management, LP | 1,547,181 | $10,985,000 | 0.83% |
| Privium Fund Management (UK) Ltd | 61,284 | $435,000 | 0.49% |
| Atom Investors LP | 30,911 | $219,000 | 0.10% |
| FEDERATED HERMES, INC. | 3,588,131 | $25,476,000 | 0.07% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 347,612 | $2,468,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,799,507 | $12,777,000 | 0.04% |